20,676 Shares of iShares Biotechnology ETF $IBB Bought by Cadent Capital Advisors LLC

Cadent Capital Advisors LLC acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 20,676 shares of the financial services provider’s stock, valued at approximately $4,353,000. iShares Biotechnology ETF accounts for 0.9% of Cadent Capital Advisors LLC’s holdings, making the stock its 29th biggest holding.

Other large investors have also recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in iShares Biotechnology ETF by 10.8% during the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock worth $1,225,767,000 after acquiring an additional 707,343 shares in the last quarter. LPL Financial LLC grew its stake in shares of iShares Biotechnology ETF by 145.9% during the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock worth $167,555,000 after purchasing an additional 589,033 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in iShares Biotechnology ETF by 1,871.5% in the fourth quarter. Janney Montgomery Scott LLC now owns 619,550 shares of the financial services provider’s stock valued at $104,562,000 after buying an additional 588,124 shares during the last quarter. Barclays PLC boosted its position in shares of iShares Biotechnology ETF by 61.5% during the 4th quarter. Barclays PLC now owns 671,941 shares of the financial services provider’s stock worth $113,403,000 after acquiring an additional 255,750 shares in the last quarter. Finally, Aptus Capital Advisors LLC increased its holdings in shares of iShares Biotechnology ETF by 9,664.1% in the 4th quarter. Aptus Capital Advisors LLC now owns 204,362 shares of the financial services provider’s stock valued at $34,490,000 after acquiring an additional 202,269 shares during the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

IBB stock traded up $5.97 during trading on Friday, hitting $206.45. 1,223,384 shares of the company’s stock were exchanged, compared to its average volume of 1,647,692. iShares Biotechnology ETF has a 52-week low of $149.09 and a 52-week high of $217.12. The business has a 50-day moving average price of $205.40 and a two-hundred day moving average price of $186.32.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were given a $0.0112 dividend. This is a negative change from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.0%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.